0.25
+0.0111(+4.59%)
Currency In USD
| Previous Close | 0.24 |
| Open | 0.25 |
| Day High | 0.29 |
| Day Low | 0.24 |
| 52-Week High | 16.32 |
| 52-Week Low | 0.24 |
| Volume | 906,395 |
| Average Volume | 881,890 |
| Market Cap | 4.95M |
| PE | -0.02 |
| EPS | -14.32 |
| Moving Average 50 Days | 3.59 |
| Moving Average 200 Days | 7.38 |
| Change | 0.01 |
If you invested $1000 in Bionomics Limited (BNOX) since IPO date, it would be worth $1.43 as of November 13, 2025 at a share price of $0.253. Whereas If you bought $1000 worth of Bionomics Limited (BNOX) shares 3 years ago, it would be worth $2.48 as of November 13, 2025 at a share price of $0.253.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation
GlobeNewswire Inc.
Dec 16, 2024 9:05 PM GMT
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders approvi
Results of Scheme Meeting
GlobeNewswire Inc.
Dec 12, 2024 9:05 PM GMT
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
GlobeNewswire Inc.
Dec 09, 2024 1:00 PM GMT
BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics